Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Sep. 30, 2020	Mar. 31, 2020
Current assets:
Cash		$ 444,372	$ 100,571
Prepaid expenses		5,854	5,460
Income tax receivable		40	36
Value-added tax receivable		0	3,009
Total current assets		450,266	109,076
Operating lease right-of-use assets		3,493	0
Property and equipment, net		136	65
Deferred offering costs		0	246
Total assets		453,895	109,387
Current liabilities:
Accounts payable		5,787	1,190
Accrued expenses		5,787	10,938
Current portion of operating lease liabilities		1,102	0
Due to Roivant Sciences Ltd.		134	3,190
Total current liabilities		12,810	15,318
Operating lease liabilities, net of current portion		2,679	0
Total liabilities		15,489	15,318
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock value	[1]	0	0
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 97,890,705 shares issued and outstanding at September 30, 2020 and 500,000,000 shares authorized, 56,455,376 shares issued and 54,655,376 shares outstanding at March 31, 2020	[1]	10	5
Additional paid-in capital	[1]	577,341	185,306
Accumulated other comprehensive loss	[1]	(222)	(16)
Accumulated deficit	[1]	(138,723)	(91,226)
Total stockholders’ equity	[1]	438,406	94,069	[2]
Total liabilities and stockholders’ equity		453,895	109,387
Series A  preferred stock
Stockholders' equity:
Preferred stock value	[1]	$ 0	$ 0

[1] Retroactively restated for the reverse recapitalization as described in Note 1.

[2] Retroactively restated for reverse recapitalization as described in Note 1.